menu
    • menu

    Find Upadacitinib manufacturers, exporters & distributors on PharmaCompass

    Zhejiang Upadacitinib

    Virtual Booth

    Contact Supplier

    Inke S.A: APIs manufacturing plant.

    Virtual Booth

    Contact Supplier

    xyz-pharma-2025-04-21

    Virtual Booth

    Contact Supplier

    Upadacitinib

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass

    Synopsis

    Related ProductsRelated Products

    Synopsis

    ACTIVE PHARMA INGREDIENTS

    32

    API Suppliers

    API Suppliers

    10

    USDMF

    US DMFs Filed

    0

    CEP/COS

    CEP/COS Certifications

    0

    JDMF

    JDMFs Filed

    0

    EU WC

    EU WC

    1

    KDMF

    KDMF

    6

    NDC API

    NDC API

    0

    VMF

    NDC API

    25

    Listed Suppliers

    Other Suppliers

    31INTERMEDIATES

    REF. STANDARDS OR IMPURITIES

    0

    EDQM

    0

    USP

    0

    JP

    0

    Others

    FINISHED DOSAGE FORMULATIONS

    35

    FDF Dossiers

    FDF Dossiers

    6

    FDA Orange Book

    FDA (Orange Book)

    1

    Europe

    Europe

    3

    Canada

    Canada

    24

    Australia

    Australia

    1

    South Africa

    South Africa

    0

    Listed Dossiers

    Listed Dossiers

    67DRUGS IN DEVELOPMENT

    FDF Dossiers

    DRUG PRODUCT COMPOSITIONS

    0RELATED EXCIPIENT COMPANIES

    0EXCIPIENTS BY APPLICATIONS

    PATENTS & EXCLUSIVITIES

    100

    US Patents

    20

    US Exclusivities

    0

    Health Canada Patents

    API REF. PRICE (USD/KG)

    $
    $ 85,711

    GLOBAL SALES INFORMATION

    US Medicaid

    622,108,917

    Annual Reports

    8,920

    Regulatory FDF Prices

    Listed Dossiers
    API/FDF Prices: Book a Demo to
    explore the features and consider
    upgrading later

    MARKET PLACE

    5

    API

    2

    FDF

    DIGITAL CONTENT

    4

    Data Compilation #PharmaFlow

    1

    Stock Recap #PipelineProspector

    0

    Weekly News Recap #Phispers

    136

    News #PharmaBuzz

    Chemistry

    Click the arrow to open the dropdown
    read-moreClick the button for full data set
    read-moreClick the button for full data set
    Also known as: 1310726-60-3, Abt-494, Rinvoq, Upadacitinib anhydrous, 4ra0kn46e0, (3s,4r)-3-ethyl-4-(1,5,7,10-tetrazatricyclo[7.3.0.02,6]dodeca-2(6),3,7,9,11-pentaen-12-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide
    Molecular Formula
    C17H19F3N6O
    Molecular Weight
    380.4  g/mol
    InChI Key
    WYQFJHHDOKWSHR-MNOVXSKESA-N
    FDA UNII
    4RA0KN46E0
    Upadacitinib
    Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by synovial inflammation and hyperplasia, autoantibody production, cartilage damage and bone destruction, leading to co-morbidities. Despite a variety of therapeutic agents available for treatment, up to 40% of the patients do not respond to current therapies, including biological therapies. The etiology of the disease is mostly unknown; however, the role of JAK as a driver of immune-mediated conditions was discovered, leading to the use of JAK as therapeutic targets for rheumatoid arthritis. To reduce dose-related toxicity (as seen with some pan-JAK inhibitors) without significantly affecting efficacy, more selective JAK1 inhibitors, upadacitinib and [filgotinib], were developed. The FDA approved Upadacitinib in August 2019 for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. In December 2019, it was additionally approved by the European Commission for the same indication in patients with inadequate response or intolerance to one or more DMARDs and can be used as monotherapy or in combination with methotrexate. Upadacitinib is marketed under the brand name RINVOQ for oral administration. It is currently being investigated in several clinical trials assessing its therapeutic effectiveness in other inflammatory diseases, such as psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, and atopic dermatitis.
    1 2D Structure

    Upadacitinib

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    (3S,4R)-3-ethyl-4-(1,5,7,10-tetrazatricyclo[7.3.0.02,6]dodeca-2(6),3,7,9,11-pentaen-12-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide
    2.1.2 InChI
    InChI=1S/C17H19F3N6O/c1-2-10-7-25(16(27)24-9-17(18,19)20)8-11(10)13-5-22-14-6-23-15-12(26(13)14)3-4-21-15/h3-6,10-11,21H,2,7-9H2,1H3,(H,24,27)/t10-,11+/m1/s1
    2.1.3 InChI Key
    WYQFJHHDOKWSHR-MNOVXSKESA-N
    2.1.4 Canonical SMILES
    CCC1CN(CC1C2=CN=C3N2C4=C(NC=C4)N=C3)C(=O)NCC(F)(F)F
    2.1.5 Isomeric SMILES
    CC[C@@H]1CN(C[C@@H]1C2=CN=C3N2C4=C(NC=C4)N=C3)C(=O)NCC(F)(F)F
    2.2 Other Identifiers
    2.2.1 UNII
    4RA0KN46E0
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. (3s,4r)-3-ethyl-4-(3h-imidazo(1,2-a)pyrrolo(2,3-e)pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)-1-pyrrolidinecarboxamide

    2. Abt-494

    3. Rinvoq

    2.3.2 Depositor-Supplied Synonyms

    1. 1310726-60-3

    2. Abt-494

    3. Rinvoq

    4. Upadacitinib Anhydrous

    5. 4ra0kn46e0

    6. (3s,4r)-3-ethyl-4-(1,5,7,10-tetrazatricyclo[7.3.0.02,6]dodeca-2(6),3,7,9,11-pentaen-12-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide

    7. (3s,4r)-3-ethyl-4-(3h-imidazo(1,2-a)pyrrolo(2,3-e)pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)-1-pyrrolidinecarboxamide

    8. (3s,4r)-3-ethyl-4-(3h-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide

    9. 1-pyrrolidinecarboxamide, 3-ethyl-4-(3h-imidazo(1,2-a)pyrrolo(2,3-e)pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)-, (3s,4r)-

    10. Mfcd30502663

    11. Upadacitinib [usan]

    12. Upadacitinib [mi]

    13. Upadacitinib, Abt-494

    14. Upadacitinib (usan/inn)

    15. Upadacitinib [inn]

    16. Upadacitinib [usan:inn]

    17. Upadacitinib (abt-494)

    18. Unii-4ra0kn46e0

    19. Upadacitinib [who-dd]

    20. Gtpl9246

    21. Schembl9991056

    22. Chembl3622821

    23. Abt 494

    24. Dtxsid901027919

    25. Upadacitinib [orange Book]

    26. Amy16528

    27. Bcp19011

    28. Ex-a1628

    29. Bdbm50503287

    30. S8162

    31. Cs-6150

    32. Db15091

    33. Abbv-599 Component Upadacitinib

    34. Abt494;abt-494;abt 494

    35. Ncgc00588874-01

    36. Ac-30326

    37. As-56379

    38. Hy-19569

    39. Upadacitinib Component Of Abbv-599

    40. J3.590.729g

    41. C72237

    42. D10994

    43. Q27074125

    44. (3s,4r)-3-ethyl-4-(3h-imidazo(1,2-a)pyrrolo(2,3-e)pyrazin- 8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide Tyrosine Kinase Inhibitor

    45. (3s,4r)-3-ethyl-4-(3h-imidazo(1,2-a)pyrrolo(2,3-e)pyrazin-8-yl)-n-(2,2,2- Trifluoroethyl)pyrrolidine-1-carboxamide

    46. Rel-(-)-(3s,4r)-3-ethyl-4-(3h-imidazo(1,2-a)pyrrolo(2,3-e)pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide

    2.4 Create Date
    2012-08-19
    3 Chemical and Physical Properties
    Molecular Weight 380.4 g/mol
    Molecular Formula C17H19F3N6O
    XLogP32.7
    Hydrogen Bond Donor Count2
    Hydrogen Bond Acceptor Count6
    Rotatable Bond Count3
    Exact Mass380.15724374 g/mol
    Monoisotopic Mass380.15724374 g/mol
    Topological Polar Surface Area78.3 Ų
    Heavy Atom Count27
    Formal Charge0
    Complexity561
    Isotope Atom Count0
    Defined Atom Stereocenter Count2
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Drug Indication

    Upadacitinib is indicated for the treatment of moderately to severely active rheumatoid arthritis or active psoriatic arthritis in adult patients who have had an inadequate response or intolerance to one or more disease-modifying anti-rheumatic drugs (DMARDs), such as methotrexate or TNF blockers. For these indications, upadacitinib may be used as monotherapy or in combination with methotrexate. Upadacitinib is also indicated for the treatment of active ankylosing spondylitis in adult patients who have an inadequate response to conventional therapy and for the treatment of moderate to severe atopic dermatitis in patients aged 12 years and older who are candidates for systemic therapy. Combining upadacitinib with other JAK inhibitors, biologic DMARDs, or other potent immunosuppressive agents is not recommended.

    FDA Label

    Rheumatoid arthritis

    RINVOQ is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). RINVOQ may be used as monotherapy or in combination with methotrexate.

    Psoriatic arthritis

    RINVOQ is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more DMARDs. RINVOQ may be used as monotherapy or in combination with methotrexate.

    Axial spondyloarthritis

    Non-radiographic axial spondyloarthritis (nr-axSpA)

    RINVOQ is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI), who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).

    Ankylosing spondylitis (AS, radiographic axial spondyloarthritis )

    RINVOQ is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy.

    Atopic dermatitis

    RINVOQ is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy.

    Ulcerative colitis

    RINVOQ is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

    Treatment of ulcerative colitis

    Treatment of Crohn's disease

    Treatment of vasculitides

    Treatment of vasculitides

    Treatment of atopic dermatitis

    Treatment of chronic idiopathic arthritis (including rheumatoid arthritis , psoriatic arthritis , spondyloarthritis and juvenile idiopathic arthritis )

    5 Pharmacology and Biochemistry
    5.1 Pharmacology

    Upadacitinib is a DMARD that works by inhibiting the Janus Kinases (JAKs), which are essential downstream cell signalling mediators of pro-inflammatory cytokines. It is believed that these pro-inflammatory cytokines play a role in many autoimmune inflammatory conditions, such as rheumatoid arthritis. In clinical trials, upadacitinib decreased the activity of pro-inflammatory interleukins, transiently increased the levels of lymphocytes, and insignificantly decreased the levels of immunoglobulins from the baseline.

    5.2 MeSH Pharmacological Classification

    Antirheumatic Agents

    Drugs that are used to treat RHEUMATOID ARTHRITIS. (See all compounds classified as Antirheumatic Agents.)

    Janus Kinase Inhibitors

    Agents that inhibit JANUS KINASES. (See all compounds classified as Janus Kinase Inhibitors.)

    5.3 ATC Code

    L04AA

    L - Antineoplastic and immunomodulating agents

    L04 - Immunosuppressants

    L04A - Immunosuppressants

    L04AA - Selective immunosuppressants

    L04AA44 - Upadacitinib

    5.4 Absorption, Distribution and Excretion

    Absorption

    Upadacitinib displays a dose-proportional pharmacokinetic profile over the therapeutic dose range. Following oral administration, the median time to reach Cmax (Tmax) ranges from 2 to 4 hours. The steady-state plasma concentrations of upadacitinib are reached within 4 days following multiple once-daily administrations, with minimal accumulation. Food intake has no clinically relevant effect on the AUC, Cmax, and Cmin of upadacitinib from the extended-release formulation.

    Route of Elimination

    Following administration of a single radio-labelled dose from the immediate-release formulation, approximately 53% of the total dose was excreted in the feces where 38% of the excreted dose was an unchanged parent drug. About 43% of the total dose was excreted in the urine, where 24% of that dose was in the unchanged parent drug form. Approximately 34% of the total dose of upadacitinib dose was excreted as metabolites.

    Volume of Distribution

    The volume of distribution of upadacitinib in a patient with rheumatoid arthritis and a body weight of 74 kg is estimated to be 224 L following oral administration of an extended-release formula. In a pharmacokinetic study consisting of healthy volunteers receiving the extended-release formulation, the steady-state volume of distribution was 294 L. Upadacitinib partitions similarly between plasma and blood cellular components with a blood to plasma ratio of 1.0.

    Clearance

    The apparent oral clearance of upadacitinib in healthy volunteers receiving the extended-release formulation was 53.7 L/h.

    5.5 Metabolism/Metabolites

    Upadacitinib predominantly undergoes CYP3A4-mediated metabolism; however, upadacitinib is a nonsensitive substrate of CYP3A4. It is also metabolized by CYP2D6 to a lesser extent. In a human radio-labelled study, about 79% of the total plasma radioactivity accounted for the parent drug, and about 13% of the total plasma radioactivity accounted for the main metabolite produced from mono-oxidation, followed by glucuronidation. There are no known active metabolites of upadacitinib.

    5.6 Biological Half-Life

    The mean terminal elimination half-life of upadacitinib ranged from 8 to 14 hours following administration of the extended-release formulation. In clinical trials, approximately 90% of upadacitinib in the systemic circulation was eliminated within 24 hours of dosing.

    5.7 Mechanism of Action

    Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease that involves the interplay of several mediators, including the immune cells (mainly T- and B-lymphocytes) and pro-inflammatory cytokines, such as the tumour necrosis factor (TNF), transforming growth factor (TGF), and interleukin 6 (IL-6). The Janus Kinase (JAK) family plays an essential role in the normal physiological functions (such as erythropoiesis), but also the signalling of pro-inflammatory cytokines that are implicated in many immune-mediated diseases. The JAK family consists of four isoforms (JAK1, JAK2, JAK3, and Tyrosine Kinase 2) that each interacts with different cytokine receptors and uniquely associates with the intracellular domains of Type I/II cytokine receptors. JAK1 is primarily involved in the signalling transduction pathways of IL-6, IFN and the common -chain cytokines, including IL-2 and IL-15. IL-6 has been closely studied in particular, as it is a major cytokine involved in B- and T-cell differentiation and the acute phase response in inflammation. Upon interaction of cytokines with their cytokine receptors, the JAKs mediate the JAK-STAT signal transduction pathway in response to receptor activation. JAKs are tyrosine kinases that cause phosphorylation of several proteins, including cytokine receptors and JAKs themselves. Phosphorylation of JAKs promotes the phosphorylation and activation of the signalling molecules called STATs, leading to their nuclear translocation, binding to DNA promoters, and target gene transcription. JAK1-mediated signalling pathways ultimately promote pro-inflammatory events, such as increased proliferation and survival of immune cells, T cell differentiation, and macrophage activation. Upadacitinib is a selective JAK1 inhibitor that has a negligible effect on JAK3, leading to an improved drug safety profile. Upadacitinib blocks the cellular processes that contribute to the inflammatory conditions in rheumatoid arthritis. In human leukocytes cellular assays, upadacitinib inhibited JAK1/3-induced phosphorylation of STAT3/5 mediated by IL-6/7.

    API Reference Price

    read-more
    read-more
    [{"dataSource":"API Export","activeIngredients":"","year":"2021","qtr":"Q2","strtotime":1624559400,"product":"UPADACITINIB - CONTROL BATCH NO. 1931150","address":"M-34, SAKET,","city":"NEW DELHI.","supplier":"TAPI TECHNOLOGY & API SERVICES","supplierCountry":"INDIA","foreign_port":"AMSTERDAM, SCHIPHOL","customer":"YUSEN LOGISTICS (BENELUX) B V","customerCountry":"NETHERLANDS","quantity":"1.00","actualQuantity":"1","unit":"KGS","unitRateFc":"134970","totalValueFC":"133345.8","currency":"USD","unitRateINR":9807000,"date":"25-Jun-2021","totalValueINR":"9807000","totalValueInUsd":"133345.8","indian_port":"DELHI AIR","hs_no":"29339990","bill_no":"2669296","productDescription":"API","marketType":"REGULATED MARKET","country":"NETHERLANDS","selfForZScoreResived":"Pharma Grade","supplierPort":"DELHI AIR","supplierAddress":"M-34, SAKET,, NEW DELHI.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2021","qtr":"Q3","strtotime":1627583400,"product":"UPADACITINIB-(SAMPLES FOR FOC)","address":"M-34, SAKET,","city":"NEW DELHI.","supplier":"TAPI TECHNOLOGY & API SERVICES","supplierCountry":"INDIA","foreign_port":"ELIZABETH","customer":"RICONPHARMA LLC","customerCountry":"UNITED STATES","quantity":"0.02","actualQuantity":"20","unit":"GMS","unitRateFc":"94.3","totalValueFC":"1823","currency":"USD","unitRateINR":6793.0765000000001,"date":"30-Jul-2021","totalValueINR":"135861.53","totalValueInUsd":"1823","indian_port":"DELHI AIR","hs_no":"29339990","bill_no":"3498363","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"DELHI AIR","supplierAddress":"M-34, SAKET,, NEW DELHI.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q4","strtotime":1667154600,"product":"UPADACITINIB HEMIHYDRATE","address":"A-2,419, CELEBRATION CITY CENTER,, GALA GYM ROAD,SOUTH BOPAL,BOPAL","city":"AHMEDABAD,GUJARAT","supplier":"APRAMEYA PHARMACHEM PVT LTD","supplierCountry":"INDIA","foreign_port":"DUBAI","customer":"TESTAPLAST RAW MATERIALS TRADING LL","customerCountry":"UNITED ARAB EMIRATES","quantity":"0.70","actualQuantity":"700","unit":"GMS","unitRateFc":"80","totalValueFC":"54178.1","currency":"EUR","unitRateINR":6368.5714285714284,"date":"31-Oct-2022","totalValueINR":"4458000","totalValueInUsd":"54178.1","indian_port":"BOMBAY AIR","hs_no":"29349100","bill_no":"5145562","productDescription":"API","marketType":"","country":"UNITED ARAB EMIRATES","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"A-2,419, CELEBRATION CITY CENTER,, GALA GYM ROAD,SOUTH BOPAL,BOPAL, AHMEDABAD,GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q1","strtotime":1677177000,"product":"UPADACITINIB API, B\/N: B665975, MFG DT:","address":"KALWE MIDC PLOT NO.8-A\/2 8\/B,TTC I NDUSTRIAL AREA KALWE BLOCK","city":"VILLAGE DIGHE NAVI MUMBAI THANE,MAH","supplier":"SANDOZ B2B","supplierCountry":"INDIA","foreign_port":"VIENNA","customer":"SANDOZ B2B","customerCountry":"AUSTRIA","quantity":"1.50","actualQuantity":"1.5","unit":"KGS","unitRateFc":"111807.5","totalValueFC":"165891.7","currency":"USD","unitRateINR":9134000,"date":"24-Feb-2023","totalValueINR":"13701000","totalValueInUsd":"165891.7","indian_port":"BOMBAY AIR","hs_no":"29339990","bill_no":"8036642","productDescription":"API","marketType":"REGULATED MARKET","country":"AUSTRIA","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"KALWE MIDC PLOT NO.8-A\/2 8\/B,TTC I NDUSTRIAL AREA KALWE BLOCK, VILLAGE DIGHE NAVI MUMBAI THANE,MAH","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1690741800,"product":"UPADACITINIB HEMIHYDRATE IN-HOUSE PHARMA","address":"H.NO.4-7-101, SCIENTIST COLONY, HABSIGUDA, NACHARAM, Contact No: 91","city":"HYDERABAD","supplier":"OPTIMUS DRUGS PRIVATE ","supplierCountry":"INDIA","foreign_port":"CAIRO","customer":"TO THE ORDER OF","customerCountry":"EGYPT","quantity":"0.07","actualQuantity":"0.065","unit":"KGS","unitRateFc":"40000","totalValueFC":"2518.6","currency":"USD","unitRateINR":3184612.2000000002,"date":"31-Jul-2023","totalValueINR":"206999.793","totalValueInUsd":"2518.6","indian_port":"HYDERABAD AIR","hs_no":"29420090","bill_no":"0","productDescription":"API","marketType":"","country":"EGYPT","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"H.NO.4-7-101, SCIENTIST COLONY, HABSIGUDA, NACHARAM, Contact No: 91, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q4","strtotime":1698345000,"product":"UPADACITINIB HEMIHYDRATE IN-HOUSE PHARMACEUTICAL FOR PHARMACEUTICAL RAW MATERIALAS PER PO","address":"PLOT NO.131,3RD FLOOR,NARMADA","city":"HYDERABAD. AP","supplier":"OPTIMUS DRUGS PRIVATE ","supplierCountry":"INDIA","foreign_port":"CAIRO","customer":"TO THE ORDER OF","customerCountry":"EGYPT","quantity":"1.50","actualQuantity":"1.5","unit":"KGS","unitRateFc":"40000","totalValueFC":"59330.1","currency":"USD","unitRateINR":3292000,"date":"27-Oct-2023","totalValueINR":"4938000","totalValueInUsd":"59330.1","indian_port":"Hyderabad Air","hs_no":"29420090","bill_no":"4923286","productDescription":"API","marketType":"","country":"EGYPT","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"PLOT NO.131,3RD FLOOR,NARMADA, HYDERABAD. AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q2","strtotime":1713983400,"product":"UPADACITINIB HEMIHYDRATE","address":"PLOT NO.131,3RD FLOOR,NARMADA","city":"HYDERABAD. AP","supplier":"OPTIMUS DRUGS PRIVATE ","supplierCountry":"INDIA","foreign_port":"DUBAI","customer":"M\/S.KING PRIME GLOBAL PROCUREMENT","customerCountry":"UNITED ARAB EMIRATES","quantity":"3.00","actualQuantity":"3","unit":"KGS","unitRateFc":"68325","totalValueFC":"215143.6","currency":"EUR","unitRateINR":5988686.25,"date":"25-Apr-2024","totalValueINR":"17966058.75","totalValueInUsd":"215143.6","indian_port":"Hyderabad Air","hs_no":"29420090","bill_no":"9396879","productDescription":"API","marketType":"","country":"UNITED ARAB EMIRATES","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"PLOT NO.131,3RD FLOOR,NARMADA, HYDERABAD. AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q2","strtotime":1717093800,"product":"UPADACITINIB (EXPORT INVOICE NO:6124010094 DT:29.05.2024)","address":"SYNO.257 258\/1, DNO.11-6\/56,","city":"VILLAGE BALANGAR POST HYDERABAD","supplier":"LEE PHARMA","supplierCountry":"INDIA","foreign_port":"MUSCAT","customer":"SMART SUPPLY INTERNATIONAL LLC,","customerCountry":"OMAN","quantity":"0.25","actualQuantity":"0.25","unit":"KGS","unitRateFc":"80000","totalValueFC":"21438.6","currency":"EUR","unitRateINR":7148000,"date":"31-May-2024","totalValueINR":"1787000","totalValueInUsd":"21438.6","indian_port":"Hyderabad Air","hs_no":"29335990","bill_no":"1315956","productDescription":"API","marketType":"","country":"OMAN","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"SYNO.257 258\/1, DNO.11-6\/56,, VILLAGE BALANGAR POST HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q4","strtotime":1729103400,"product":"UPADACITINIB","address":"HOSTER LABS PRIVATE LIMITED","city":"HYDERABAD","supplier":"HOSTER LABS PRIVATE LIMITED","supplierCountry":"INDIA","foreign_port":"AMSTERDAM, SCHIPHOL","customer":"CYBERFREIGHT BV (C\/O MEDICA PHARMA)","customerCountry":"NETHERLANDS","quantity":"0.01","actualQuantity":"10","unit":"GMS","unitRateFc":"100","totalValueFC":"971","currency":"USD","unitRateINR":8158.8000000000002,"date":"17-Oct-2024","totalValueINR":"81588","totalValueInUsd":"971","indian_port":"Hyderabad Air","hs_no":"29349990","bill_no":"4878558","productDescription":"API","marketType":"REGULATED MARKET","country":"NETHERLANDS","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"HOSTER LABS PRIVATE LIMITED, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q4","strtotime":1730917800,"product":"UPADACITINIB","address":"HOSTER LABS PRIVATE LIMITED","city":"HYDERABAD","supplier":"HOSTER LABS PRIVATE LIMITED","supplierCountry":"INDIA","foreign_port":"BAGDAD, METROPOLITAN","customer":"SAMA ALFAYHAA PHARMACEUTICAL","customerCountry":"IRAQ","quantity":"0.50","actualQuantity":"500","unit":"GMS","unitRateFc":"29","totalValueFC":"14172.3","currency":"USD","unitRateINR":2391.9417000000003,"date":"07-Nov-2024","totalValueINR":"1195970.85","totalValueInUsd":"14172.3","indian_port":"Hyderabad Air","hs_no":"29349990","bill_no":"5430859","productDescription":"API","marketType":"","country":"IRAQ","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"HOSTER LABS PRIVATE LIMITED, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q4","strtotime":1734719400,"product":"UPADACITINIB","address":"HOSTER LABS PRIVATE LIMITED","city":"HYDERABAD","supplier":"HOSTER LABS PRIVATE LIMITED","supplierCountry":"INDIA","foreign_port":"SEOUL - INCHEON INT\\'","customer":"PHARMAPIA CO. LTD","customerCountry":"KOREA, REPUBLIC OF","quantity":"0.20","actualQuantity":"200","unit":"GMS","unitRateFc":"45","totalValueFC":"8890.3","currency":"USD","unitRateINR":3777,"date":"21-Dec-2024","totalValueINR":"755400","totalValueInUsd":"8890.3","indian_port":"Hyderabad Air","hs_no":"29349990","bill_no":"6658273","productDescription":"API","marketType":"REGULATED MARKET","country":"REPUBLIC OF KOREA","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"HOSTER LABS PRIVATE LIMITED, HYDERABAD","customerAddress":""},{"dataSource":"API Import","activeIngredients":"","year":"2021","qtr":"Q3","strtotime":1627497000,"product":"UPADACITINIB, TL.NO. TL\/NZ\/21\/000393, BATCH V2994\/0, 21040 (FOR R&D)","address":"ACME PLAZA, ANDHERI KURLA ROAD,ANDHERI EAST","city":"MUMBAI, MAHARASHTRA.","supplier":"CRYSTAL PHARMA S.A.U","supplierCountry":"SPAIN","foreign_port":"MADRID","customer":"SUN PHARMACEUTICAL INDUSTRIES LIMITED","customerCountry":"INDIA","quantity":"0.15","actualQuantity":"0.15","unit":"KGS","unitRateFc":"125000","totalValueFC":"18969.7","currency":"USD","unitRateINR":"9425000","date":"29-Jul-2021","totalValueINR":"1413750","totalValueInUsd":"18969.7","indian_port":"DELHI AIR","hs_no":"29335990","bill_no":"4859793","productDescription":"API","marketType":"REGULATED MARKET","country":"SPAIN","selfForZScoreResived":"Pharma Grade","supplierPort":"MADRID","supplierAddress":"","customerAddress":"ACME PLAZA, ANDHERI KURLA ROAD,ANDHERI EAST"},{"dataSource":"API Import","activeIngredients":"","year":"2021","qtr":"Q3","strtotime":1627497000,"product":"UPADACITINIB, TL.NO. TL\/NZ\/21\/000393, BATCH Z2994\/0 UPD-LCN-397(FOR R&D)","address":"ACME PLAZA, ANDHERI KURLA ROAD,ANDHERI EAST","city":"MUMBAI, MAHARASHTRA.","supplier":"CRYSTAL PHARMA S.A.U","supplierCountry":"SPAIN","foreign_port":"MADRID","customer":"SUN PHARMACEUTICAL INDUSTRIES LIMITED","customerCountry":"INDIA","quantity":"0.20","actualQuantity":"0.2","unit":"KGS","unitRateFc":"125000","totalValueFC":"25292.9","currency":"USD","unitRateINR":"9425000","date":"29-Jul-2021","totalValueINR":"1885000","totalValueInUsd":"25292.9","indian_port":"DELHI AIR","hs_no":"29335990","bill_no":"4859793","productDescription":"API","marketType":"REGULATED MARKET","country":"SPAIN","selfForZScoreResived":"Pharma Grade","supplierPort":"MADRID","supplierAddress":"","customerAddress":"ACME PLAZA, ANDHERI KURLA ROAD,ANDHERI EAST"},{"dataSource":"API Import","activeIngredients":"","year":"2021","qtr":"Q3","strtotime":1630521000,"product":"UPADACITINIB","address":"2ND FLOOR, CHINUBHAI CENTRE,OFF. NEHRU BRIDGE, ASHRAM ROAD,","city":"AHMEDABAD, GUJARAT","supplier":"CRYSTAL PHARMA S.A.U","supplierCountry":"SPAIN","foreign_port":"#N\/A","customer":"INTAS PHARMACEUTICALS","customerCountry":"INDIA","quantity":"0.50","actualQuantity":"0.5","unit":"KGS","unitRateFc":"150000","totalValueFC":"76675.8","currency":"USD","unitRateINR":"11280000","date":"02-Sep-2021","totalValueINR":"5640000","totalValueInUsd":"76675.8","indian_port":"BOMBAY AIR","hs_no":"29339990","bill_no":"5280559","productDescription":"API","marketType":"REGULATED MARKET","country":"SPAIN","selfForZScoreResived":"Pharma Grade","supplierPort":"#N\/A","supplierAddress":"","customerAddress":"2ND FLOOR, CHINUBHAI CENTRE,OFF. NEHRU BRIDGE, ASHRAM ROAD,"},{"dataSource":"API Import","activeIngredients":"","year":"2021","qtr":"Q4","strtotime":1633026600,"product":"ACTIVE PHARMACEUTICALS INGREDIENTS (UPADACITINIB) (V2994\/0 21020)(VALUE FOR CUSTOMS PURPOSE,NO COMMERCIAL VALUE)","address":"KALWE MIDC PLOT NO.8-A\/2 8\/B,TTC I NDUSTRIAL AREA KALWE BLOCK","city":"VILLAGE DIGHE NAVI MUMBAI THANE,MAH","supplier":"SANDOZ B2B","supplierCountry":"SPAIN","foreign_port":"NA","customer":"SANDOZ B2B","customerCountry":"INDIA","quantity":"4.15","actualQuantity":"4.148","unit":"KGS","unitRateFc":"115000","totalValueFC":"573841.6","currency":"USD","unitRateINR":"10363455","date":"01-Oct-2021","totalValueINR":"42987611.34","totalValueInUsd":"573841.6","indian_port":"BOMBAY AIR","hs_no":"29339990","bill_no":"5663595","productDescription":"API","marketType":"REGULATED MARKET","country":"SPAIN","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"KALWE MIDC PLOT NO.8-A\/2 8\/B,TTC I NDUSTRIAL AREA KALWE BLOCK"},{"dataSource":"API Import","activeIngredients":"","year":"2022","qtr":"Q1","strtotime":1647887400,"product":"UPADACITINIB (FOR R &D PURPOSE)","address":"CORPORATE HOUSE, NR. SOLA BRIDGE,, S.G. HIGHWAY, THALTEJ","city":"AHMEDABAD,GUJARAT","supplier":"CURIA","supplierCountry":"SPAIN","foreign_port":"NA","customer":"INTAS PHARMACEUTICALS","customerCountry":"INDIA","quantity":"1.10","actualQuantity":"1.1","unit":"KGS","unitRateFc":"150000","totalValueFC":"166473.1","currency":"USD","unitRateINR":"11535000","date":"22-Mar-2022","totalValueINR":"12688500","totalValueInUsd":"166473.1","indian_port":"BOMBAY AIR","hs_no":"29339990","bill_no":"7958202","productDescription":"API","marketType":"REGULATED MARKET","country":"SPAIN","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"CORPORATE HOUSE, NR. SOLA BRIDGE,, S.G. HIGHWAY, THALTEJ"},{"dataSource":"API Import","activeIngredients":"","year":"2022","qtr":"Q2","strtotime":1655058600,"product":"UPADACITINIB (FOR R & D PURPOSE)","address":"CORPORATE HOUSE, NR. SOLA BRIDGE,, S.G. HIGHWAY, THALTEJ","city":"AHMEDABAD,GUJARAT","supplier":"CURIA","supplierCountry":"SPAIN","foreign_port":"NA","customer":"INTAS PHARMACEUTICALS","customerCountry":"INDIA","quantity":"0.66","actualQuantity":"0.664","unit":"KGS","unitRateFc":"125000","totalValueFC":"83515.7","currency":"USD","unitRateINR":"9812500","date":"13-Jun-2022","totalValueINR":"6515500","totalValueInUsd":"83515.7","indian_port":"BOMBAY AIR","hs_no":"29339990","bill_no":"9086701","productDescription":"API","marketType":"REGULATED MARKET","country":"SPAIN","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"CORPORATE HOUSE, NR. SOLA BRIDGE,, S.G. HIGHWAY, THALTEJ"},{"dataSource":"API Import","activeIngredients":"","year":"2022","qtr":"Q3","strtotime":1658255400,"product":"UPADACITINIB (BATCH NO: V29948\/0 21080)","address":"SPARC TANDALJA","city":"VADODARA","supplier":"CURIA","supplierCountry":"SPAIN","foreign_port":"NA","customer":"SUN PHARMACEUTICAL INDUSTRIES LIMITED","customerCountry":"INDIA","quantity":"4.20","actualQuantity":"4.2","unit":"KGS","unitRateFc":"85000","totalValueFC":"358721.6","currency":"USD","unitRateINR":"6791500","date":"20-Jul-2022","totalValueINR":"28524300","totalValueInUsd":"358721.6","indian_port":"BOMBAY AIR","hs_no":"29339990","bill_no":"9640012","productDescription":"API","marketType":"REGULATED MARKET","country":"SPAIN","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"SPARC TANDALJA"},{"dataSource":"API Import","activeIngredients":"","year":"2022","qtr":"Q3","strtotime":1658773800,"product":"UPADACITINIB - BATCH NO - V2994\/0 22020","address":"KALWE MIDC PLOT NO.8-A\/2 8\/B,TTC I NDUSTRIAL AREA KALWE BLOCK","city":"VILLAGE DIGHE NAVI MUMBAI THANE,MAH","supplier":"CURIA","supplierCountry":"SPAIN","foreign_port":"NA","customer":"SANDOZ B2B","customerCountry":"INDIA","quantity":"8.00","actualQuantity":"8","unit":"KGS","unitRateFc":"106000","totalValueFC":"863287.1","currency":"USD","unitRateINR":"8580700","date":"26-Jul-2022","totalValueINR":"68645600","totalValueInUsd":"863287.1","indian_port":"BOMBAY AIR","hs_no":"29339990","bill_no":"9726983","productDescription":"API","marketType":"REGULATED MARKET","country":"SPAIN","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"KALWE MIDC PLOT NO.8-A\/2 8\/B,TTC I NDUSTRIAL AREA KALWE BLOCK"},{"dataSource":"API Import","activeIngredients":"","year":"2022","qtr":"Q3","strtotime":1659292200,"product":"UPADACITINIB (FOR R & D PURPOSE)","address":"CORPORATE HOUSE, NR. SOLA BRIDGE,, S.G. HIGHWAY, THALTEJ","city":"AHMEDABAD,GUJARAT","supplier":"CURIA","supplierCountry":"SPAIN","foreign_port":"NA","customer":"INTAS PHARMACEUTICALS","customerCountry":"INDIA","quantity":"0.61","actualQuantity":"0.612","unit":"KGS","unitRateFc":"125000","totalValueFC":"77829.5","currency":"USD","unitRateINR":"10118750","date":"01-Aug-2022","totalValueINR":"6192675","totalValueInUsd":"77829.5","indian_port":"BOMBAY AIR","hs_no":"29339990","bill_no":"9814111","productDescription":"API","marketType":"REGULATED MARKET","country":"SPAIN","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"CORPORATE HOUSE, NR. SOLA BRIDGE,, S.G. HIGHWAY, THALTEJ"},{"dataSource":"API Import","activeIngredients":"","year":"2022","qtr":"Q3","strtotime":1659292200,"product":"UPADACITINIB (FOR R & D PURPOSE)","address":"CORPORATE HOUSE, NR. SOLA BRIDGE,, S.G. HIGHWAY, THALTEJ","city":"AHMEDABAD,GUJARAT","supplier":"CURIA","supplierCountry":"SPAIN","foreign_port":"NA","customer":"INTAS PHARMACEUTICALS","customerCountry":"INDIA","quantity":"1.00","actualQuantity":"1","unit":"KGS","unitRateFc":"125000","totalValueFC":"127172.5","currency":"USD","unitRateINR":"10118750","date":"01-Aug-2022","totalValueINR":"10118750","totalValueInUsd":"127172.5","indian_port":"BOMBAY AIR","hs_no":"29339990","bill_no":"9814111","productDescription":"API","marketType":"REGULATED MARKET","country":"SPAIN","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"CORPORATE HOUSE, NR. SOLA BRIDGE,, S.G. HIGHWAY, THALTEJ"},{"dataSource":"API Import","activeIngredients":"","year":"2022","qtr":"Q4","strtotime":1666031400,"product":"UPADACITINIB - BATCH NO - V2994\/0 22120 (IGCRD)","address":"KALWE MIDC PLOT NO.8-A\/2 8\/B,TTC I NDUSTRIAL AREA KALWE BLOCK","city":"VILLAGE DIGHE NAVI MUMBAI THANE,MAH","supplier":"CURIA","supplierCountry":"SPAIN","foreign_port":"NA","customer":"SANDOZ B2B","customerCountry":"INDIA","quantity":"3.00","actualQuantity":"3","unit":"KGS","unitRateFc":"106000","totalValueFC":"318640.7","currency":"USD","unitRateINR":"8739700","date":"18-Oct-2022","totalValueINR":"26219100","totalValueInUsd":"318640.7","indian_port":"BOMBAY AIR","hs_no":"29339990","bill_no":"2931324","productDescription":"API","marketType":"REGULATED MARKET","country":"SPAIN","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"KALWE MIDC PLOT NO.8-A\/2 8\/B,TTC I NDUSTRIAL AREA KALWE BLOCK"},{"dataSource":"API Import","activeIngredients":"","year":"2023","qtr":"Q4","strtotime":1701714600,"product":"LUT-7 ACTIVE PHARMACEUTICALS INGREDIENTS (UPADACITINIB) (CASNUMBER 1310726-60-3 BATCH V2994\/0 22171)","address":"SANDOZ HOUSE","city":"MUMBAI ,MAHARASHTRA","supplier":"CURIA","supplierCountry":"SPAIN","foreign_port":"MADRID","customer":"SANDOZ B2B","customerCountry":"INDIA","quantity":"0.03","actualQuantity":"0.025","unit":"KGS","unitRateFc":"104000","totalValueFC":"2897.9","currency":"EUR","unitRateINR":"9649347.6","date":"05-Dec-2023","totalValueINR":"241233.69","totalValueInUsd":"2897.9","indian_port":"Bombay Air","hs_no":"29339990","bill_no":"9082299","productDescription":"API","marketType":"REGULATED MARKET","country":"SPAIN","selfForZScoreResived":"Pharma Grade","supplierPort":"MADRID","supplierAddress":"PARQUE TECHNOLOGICO DE BOECILLOPARCELA 105 47151 BOECILLOVALLADOLID SPAIN","customerAddress":"SANDOZ HOUSE"},{"dataSource":"API Import","activeIngredients":"","year":"2024","qtr":"Q3","strtotime":1727634600,"product":"UPADACITINIB SUCCINIC ACID (QTY:250 GMS, VALUE:USD 16500)","address":"H.NO. 8-2-337,BESIDE TV9 OFFICE","city":"HYDERABAD ANDHRA PRADESH","supplier":"GYMA LABORATORIES OF AMERICA","supplierCountry":"CHINA","foreign_port":"NANJING","customer":"DR. REDDY\\'S LABORATORIES","customerCountry":"INDIA","quantity":"0.25","actualQuantity":"0.25","unit":"KGS","unitRateFc":"66000","totalValueFC":"17162","currency":"USD","unitRateINR":"5752800","date":"30-Sep-2024","totalValueINR":"1438200","totalValueInUsd":"17162","indian_port":"Hyderabad Air","hs_no":"29171930","bill_no":"5880598","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"NANJING","supplierAddress":"210 CROSSWAYS PARK DRIVE, SUITE 100 , WOODBURY, NY 11797 , UNITED STATE S United States","customerAddress":"H.NO. 8-2-337,BESIDE TV9 OFFICE"}]
    25-Jun-2021
    21-Dec-2024
    KGS
    overview
    Loading...

    Average Price (USD/KGS)

    Number of Transactions

    Total Quantity (KGS)

    Total Value (USD)

    Quantity (KGS) & Unit rate (USD/KGS) over time

    API/FDF Prices: Book a Demo to explore the features and consider upgrading later

    API Imports and Exports

    Importing Country Total Quantity
    (KGS)    		 Average Price
    (USD/KGS)    		 Number of Transactions

    Upgrade, download data, analyse, strategize, subscribe with us contact

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    DATA COMPILATION #PharmaFlow

    read-more
    read-more

    STOCK RECAP #PipelineProspector

    read-more
    read-more

    NEWS #PharmaBuzz

    read-more
    read-more
    Rinvoq Recieves FDA approved for Giant Cell Arteritis
    Rinvoq Recieves FDA approved for Giant Cell Arteritis

    29 Apr 2025

    // PRESS RELEASE

    https://news.abbvie.com/2025-04-29-RINVOQ-R-upadacitinib-Receives-U-S-FDA-Approval-for-Giant-Cell-Arteritis-GCA

    PRESS RELEASE
    29 Apr 2025
    Share Share
    AbbVie Announces EMA Approval of Rinvoqa For Giant Cell Arteritis
    AbbVie Announces EMA Approval of Rinvoqa For Giant Cell Arteritis

    09 Apr 2025

    // PRESS RELEASE

    https://news.abbvie.com/2025-04-08-AbbVie-Announces-European-Commission-Approval-of-RINVOQ-R-upadacitinib-for-the-Treatment-of-Adults-with-Giant-Cell-Arteritis#:~:text=NORTH%20CHICAGO%2C%20Ill.%2C%20April,(GCA)%20in%20adult%20patients.

    PRESS RELEASE
    09 Apr 2025
    Share Share
    AbbVie projects over $31B in Skyrizi, Rinvoq sales by 2027
    AbbVie projects over $31B in Skyrizi, Rinvoq sales by 2027

    01 Feb 2025

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/abbvie-jacks-2027-sales-projection-skyrizi-and-rinvoq-31b

    FIERCE PHARMA
    01 Feb 2025
    Share Share
    AbbVie looks to extend Rinvoq's reach with filings for giant cell arteritis
    AbbVie looks to extend Rinvoq's reach with filings for giant cell arteritis

    13 Jul 2024

    // PRESS RELEASE

    https://news.abbvie.com/2024-07-12-AbbVie-Submits-Regulatory-Applications-to-FDA-and-EMA-for-Upadacitinib-RINVOQ-R-in-Giant-Cell-Arteritis

    PRESS RELEASE
    13 Jul 2024
    Share Share
    RINVOQ Available For Pediatric Polyarticular JIA And Psoriatic Arthritis
    RINVOQ Available For Pediatric Polyarticular JIA And Psoriatic Arthritis

    04 Jun 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/rinvoq-upadacitinib-now-available-for-pediatric-patients-two-years-and-older-with-polyarticular-juvenile-idiopathic-arthritis-and-psoriatic-arthritis-302162639.html

    PR NEWSWIRE
    04 Jun 2024
    Share Share
    J&J acquires experimental skin disorder drug for $1.25 billion
    J&J acquires experimental skin disorder drug for $1.25 billion

    29 May 2024

    // Ben Fidler BIOPHARMADIVE

    https://www.biopharmadive.com/news/johnson-johnson-numab-yellow-jersey-bispecific-atopic-dermatitis-eczema/717179/

    Ben Fidler BIOPHARMADIVE
    29 May 2024
    Share Share

    Global Sales Information

    Do you need Business Intel? Ask us

    Market Place

    Do you need sourcing support? Ask us

    Patents & EXCLUSIVITIES

    Check the patents & exclusivity for this product

    ABOUT THIS PAGE

    Looking for 1310726-60-3 / Upadacitinib API manufacturers, exporters & distributors?

    Upadacitinib manufacturers, exporters & distributors 1

    30

    PharmaCompass offers a list of Upadacitinib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Upadacitinib manufacturer or Upadacitinib supplier for your needs.

    Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Upadacitinib manufacturer or Upadacitinib supplier.

    PharmaCompass also assists you with knowing the Upadacitinib API Price utilized in the formulation of products. Upadacitinib API Price is not always fixed or binding as the Upadacitinib Price is obtained through a variety of data sources. The Upadacitinib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

    API | Excipient name

    Upadacitinib

    Synonyms

    1310726-60-3, Abt-494, Rinvoq, Upadacitinib anhydrous, 4ra0kn46e0, (3s,4r)-3-ethyl-4-(1,5,7,10-tetrazatricyclo[7.3.0.02,6]dodeca-2(6),3,7,9,11-pentaen-12-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide

    Cas Number

    1310726-60-3

    Unique Ingredient Identifier (UNII)

    4RA0KN46E0

    About Upadacitinib

    Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by synovial inflammation and hyperplasia, autoantibody production, cartilage damage and bone destruction, leading to co-morbidities. Despite a variety of therapeutic agents available for treatment, up to 40% of the patients do not respond to current therapies, including biological therapies. The etiology of the disease is mostly unknown; however, the role of JAK as a driver of immune-mediated conditions was discovered, leading to the use of JAK as therapeutic targets for rheumatoid arthritis. To reduce dose-related toxicity (as seen with some pan-JAK inhibitors) without significantly affecting efficacy, more selective JAK1 inhibitors, upadacitinib and [filgotinib], were developed. The FDA approved Upadacitinib in August 2019 for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. In December 2019, it was additionally approved by the European Commission for the same indication in patients with inadequate response or intolerance to one or more DMARDs and can be used as monotherapy or in combination with methotrexate. Upadacitinib is marketed under the brand name RINVOQ for oral administration. It is currently being investigated in several clinical trials assessing its therapeutic effectiveness in other inflammatory diseases, such as psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, and atopic dermatitis.

    Upadacitinib Manufacturers

    A Upadacitinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Upadacitinib, including repackagers and relabelers. The FDA regulates Upadacitinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Upadacitinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

    click here to find a list of Upadacitinib manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

    Upadacitinib Suppliers

    A Upadacitinib supplier is an individual or a company that provides Upadacitinib active pharmaceutical ingredient (API) or Upadacitinib finished formulations upon request. The Upadacitinib suppliers may include Upadacitinib API manufacturers, exporters, distributors and traders.

    click here to find a list of Upadacitinib suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

    Upadacitinib USDMF

    A Upadacitinib DMF (Drug Master File) is a document detailing the whole manufacturing process of Upadacitinib active pharmaceutical ingredient (API) in detail. Different forms of Upadacitinib DMFs exist exist since differing nations have different regulations, such as Upadacitinib USDMF, ASMF (EDMF), JDMF, CDMF, etc.

    A Upadacitinib DMF submitted to regulatory agencies in the US is known as a USDMF. Upadacitinib USDMF includes data on Upadacitinib's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Upadacitinib USDMF is kept confidential to protect the manufacturer’s intellectual property.

    click here to find a list of Upadacitinib suppliers with USDMF on PharmaCompass.

    Upadacitinib KDMF

    In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.

    Pharmaceutical companies submit a Upadacitinib Drug Master File in Korea (Upadacitinib KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Upadacitinib. The MFDS reviews the Upadacitinib KDMF as part of the drug registration process and uses the information provided in the Upadacitinib KDMF to evaluate the safety and efficacy of the drug.

    After submitting a Upadacitinib KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Upadacitinib API can apply through the Korea Drug Master File (KDMF).

    click here to find a list of Upadacitinib suppliers with KDMF on PharmaCompass.

    Upadacitinib NDC

    National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Upadacitinib as an active pharmaceutical ingredient (API).

    Finished drug products

    The FDA updates the NDC directory daily. The NDC numbers for Upadacitinib API and other APIs are published in this directory by the FDA.

    Unfinished drugs

    The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

    Pharmaceutical companies that manufacture Upadacitinib as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

    Compounded drug products

    The NDC directory also contains data on finished compounded human drug products that contain Upadacitinib and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Upadacitinib NDC to their finished compounded human drug products, they may choose to do so.

    click here to find a list of Upadacitinib suppliers with NDC on PharmaCompass.

    Upadacitinib GMP

    Upadacitinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

    GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

    PharmaCompass offers a list of Upadacitinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Upadacitinib GMP manufacturer or Upadacitinib GMP API supplier for your needs.

    Upadacitinib CoA

    A Upadacitinib CoA (Certificate of Analysis) is a formal document that attests to Upadacitinib's compliance with Upadacitinib specifications and serves as a tool for batch-level quality control.

    Upadacitinib CoA mostly includes findings from lab analyses of a specific batch. For each Upadacitinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

    Upadacitinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Upadacitinib EP), Upadacitinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Upadacitinib USP).

    Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
    For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search